Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 1 examiners • 0 of 4 (0%) have an AI response strategy ready
Calliditas Therapeutics AB has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. Remarkably, all 4 of these actions are assigned to a single examiner, ANTHOPOLOS, PETER. Despite this concentration of personnel, the matters are split between 2 distinct art units.
ANTHOPOLOS, PETER is the busiest examiner, holding all 4 pending office actions. This concentration with 1 distinct examiner is highly unusual and provides a unique opportunity for practitioners to develop a very focused relationship and strategy with this individual. While the 4 pending office actions are in 2 distinct art units, the fact that a single examiner is reviewing all of them allows for a highly consistent advocacy approach across the company's current active portfolio. Success with the 1 distinct examiner will largely determine the overall success of the company's current patenting efforts. The limited number of examiners allows for a very targeted and consistent advocacy approach. Practitioners can leverage insights gained from one application to inform the strategy for the others, as the 2 distinct art units likely share similar examination standards. This concentration is a significant advantage for maintaining a unified legal front across the 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANTHOPOLOS, PETER | 4 | 57.4% | +58.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19303799 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 51d overdue |
| 19194972 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | — |
| 18352811 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19303799 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 51d overdue |
| 19304103 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | — |
| 19194972 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | — |
| 18352811 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | — |
| Art Unit | Apps |
|---|---|
| 1611 | 3 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19303799 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 1611 | §103§112 | Final Rejection | 51d overdue | Pending | Aug 19, 2025 |
| 19304103 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 1611 | §112 | Non-Final OA | — | Pending | Aug 19, 2025 |
| 19194972 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 1611 | §103§112 | Final Rejection | — | Pending | Apr 30, 2025 |
| 18352811 | PHARMACEUTICAL COMPOSITIONS | ANTHOPOLOS, PETER | 1600 | §103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCalliditas Therapeutics AB has 4 pending office actions as of October 2026, spread across 2 art units and 1 examiners.
Peter Anthopolos has the most, with 4 of Calliditas Therapeutics AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
